staurosporine has been researched along with Burkitt Lymphoma in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ding, P; Ge, X; Hou, Y; Hu, W; Jiang, Z; Li, L; Lv, X; Wang, Q; Xu, Y; Zeng, H; Zhang, W; Zhou, D | 1 |
| Araki, S; Ebara, S; Furukawa, Y; Kitamura, D; Mizuta, M; Mizuta, R; Shiokawa, D; Suzuki, K; Tanuma, S | 1 |
| Grunicke, H; Hofmann, J; Jackman, J; Kohn, KW; O'Connor, PM; Schubert, C; Ueberall, F | 1 |
| Eastman, A; Fan, S; O'Connor, PM; Sausville, EA; Wang, Q; Worland, PJ | 1 |
| Bigas, A; Chernukhin, IV; Delgado, MD; Klenova, EM; León, J | 1 |
| Amé, P; Cahn, JY; Clark, H; Dang, CV; Fest, T; Haughey, C; Kuttler, F; Mougin, C; Raffeld, M | 1 |
| Bieszczad, CK; Cleaveland, ES; Craig, RW; Ma, Y; Mohandas, TK; Park, JP; Vrana, JA | 1 |
| Auberger, P; Bertolotto, C; Cousin, JL; Herrant, M; Luciano, F; Mari, B; Ricci, JE | 1 |
| Daibata, M; Humphreys, RE; Sairenji, T; Takada, K | 1 |
9 other study(ies) available for staurosporine and Burkitt Lymphoma
| Article | Year |
|---|---|
Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis.
Topics: Animals; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, SCID; Neoplasm Proteins; Rituximab; Staurosporine; Xenograft Model Antitumor Assays | 2018 |
DNase gamma-dependent and -independent apoptotic DNA fragmentations in Ramos Burkitt's lymphoma cell line.
Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Cell Nucleus; Deoxyribonucleases; DNA Fragmentation; Endodeoxyribonucleases; Enzyme Inhibitors; Humans; Poly-ADP-Ribose Binding Proteins; Staurosporine | 2009 |
The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents.
Topics: Alkaloids; Antineoplastic Agents; Burkitt Lymphoma; CDC2 Protein Kinase; Cell Cycle; Cell Line; DNA Damage; Dose-Response Relationship, Radiation; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; G2 Phase; Humans; Kinetics; Mechlorethamine; Nocodazole; Phospholipid Ethers; Protein Kinase C; Radiation, Ionizing; Staurosporine; Tumor Cells, Cultured | 1994 |
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Topics: Alkaloids; Antineoplastic Agents; Burkitt Lymphoma; CDC2 Protein Kinase; Cell Division; Cell Survival; Cisplatin; Colonic Neoplasms; Cyclin B; Cyclin B1; Cyclins; Drug Synergism; Flow Cytometry; G2 Phase; Gamma Rays; Genes, p53; Humans; Immunoblotting; Mitotic Index; Mutation; Precipitin Tests; Radiation Dosage; Staurosporine; Tumor Cells, Cultured | 1996 |
Differential expression and phosphorylation of CTCF, a c-myc transcriptional regulator, during differentiation of human myeloid cells.
Topics: Blotting, Northern; Blotting, Western; Burkitt Lymphoma; CCCTC-Binding Factor; Cell Differentiation; Cytarabine; Dimethyl Sulfoxide; DNA-Binding Proteins; Down-Regulation; Erythrocytes; Gene Expression Regulation; Humans; Isoelectric Focusing; Leukemia, Myeloid; Leukocytes; Megakaryocytes; Phosphorylation; Proto-Oncogene Proteins c-myc; Repressor Proteins; RNA Processing, Post-Transcriptional; Staurosporine; Tetradecanoylphorbol Acetate; Transcription Factors; Tretinoin; Tumor Cells, Cultured | 1999 |
c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
Topics: Alleles; Animals; Apoptosis; Burkitt Lymphoma; Cell Line; Cell Transformation, Neoplastic; Conserved Sequence; Phenotype; Point Mutation; Proto-Oncogene Proteins c-myc; Rats; Receptors, Estrogen; Recombinant Fusion Proteins; Staurosporine; Tamoxifen; Trans-Activators; Transfection; Tumor Necrosis Factor-alpha | 2001 |
An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Burkitt Lymphoma; Camptothecin; Cell Survival; Culture Media, Serum-Free; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2002 |
T and B leukemic cell lines exhibit different requirements for cell death: correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt's lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; Blotting, Western; Burkitt Lymphoma; Caspases; Cell Survival; Cytochrome c Group; Deoxyribonucleases; DNA Fragmentation; DNA Primers; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, B-Cell; Leukemia, T-Cell; Membrane Glycoproteins; Poly-ADP-Ribose Binding Proteins; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata.
Topics: Alkaloids; Antibodies, Anti-Idiotypic; B-Lymphocytes; Burkitt Lymphoma; Calcimycin; Cyclic AMP; Diglycerides; Herpesvirus 4, Human; Humans; Immunoglobulin G; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Peptides; Protein Kinase C; Receptors, Antigen, B-Cell; Signal Transduction; Staurosporine; Trifluoperazine; Tumor Cells, Cultured; Virus Replication; Wasp Venoms | 1990 |